Cargando…

Bevacizumab in the treatment of NSCLC: patient selection and perspectives

Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted approaches have been developed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Alessia E, Priolo, Domenico, Antonelli, Giovanna, Libra, Massimo, McCubrey, James A, Ferraù, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733913/ https://www.ncbi.nlm.nih.gov/pubmed/29276417 http://dx.doi.org/10.2147/LCTT.S110306

Ejemplares similares

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
por: Pappalardo, Francesco, et al.
Publicado: (2016)

Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer
por: Candido, Saverio, et al.
Publicado: (2014)

Emerging targeted therapies for melanoma treatment (Review)
por: RUSSO, ANGELA, et al.
Publicado: (2014)

Bioinformatic analysis of the LCN2–SLC22A17–MMP9 network in cancer: The role of DNA methylation in the modulation of tumor microenvironment
por: Candido, Saverio, et al.
Publicado: (2022)

MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma
por: Falzone, Luca, et al.
Publicado: (2016)

Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer
por: Falzone, Luca, et al.
Publicado: (2016)

Cutaneous melanoma: From pathogenesis to therapy (Review)
por: Leonardi, Giulia C., et al.
Publicado: (2018)

Recent progress in targeting cancer
por: Demidenko, Zoya N., et al.
Publicado: (2011)

Recent discoveries in the cycling, growing and aging of the p53 field
por: McCubrey, James A., et al.
Publicado: (2012)

Where are we with understanding of COVID-19?
por: Akula, Shaw M., et al.
Publicado: (2020)

Where are we with understanding of COVID-19?
por: Akula, Shaw M., et al.
Publicado: (2020)

Cell-to-cell lactate shuttle operates in heart and is important in age-related heart failure
por: Gizak, Agnieszka, et al.
Publicado: (2020)

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells
por: Taylor, Jackson R., et al.
Publicado: (2011)

Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression
por: Steelman, Linda S., et al.
Publicado: (2017)

Analysis of the B-RAF(V600E) mutation in cutaneous melanoma patients with occupational sun exposure
por: CANDIDO, SAVERIO, et al.
Publicado: (2014)

Foreword for the special issue advances in COVID-19: Biology and clinic
por: McCubrey, James A., et al.
Publicado: (2020)

Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity
por: Chappell, William H., et al.
Publicado: (2012)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)

Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC
por: Li, Butuo, et al.
Publicado: (2018)

Neuron-derived transthyretin modulates astrocytic glycolysis in hormone-independent manner
por: Zawiślak, Alina, et al.
Publicado: (2017)

TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer
por: Akula, Shaw M., et al.
Publicado: (2020)

Neoadjuvant therapy for locally advanced melanoma: new strategies with targeted therapies
por: La Greca, Michele, et al.
Publicado: (2014)

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells
por: Abrams, Stephen L., et al.
Publicado: (2017)

Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
por: Bevelacqua, Valentina, et al.
Publicado: (2012)

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
por: Steelman, Linda S., et al.
Publicado: (2011)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer
por: Banna, Giuseppe L., et al.
Publicado: (2017)

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
por: Chappell, William H., et al.
Publicado: (2020)

The Reverse Warburg Effect Is Associated with Fbp2-Dependent Hif1α Regulation in Cancer Cells Stimulated by Fibroblasts
por: Duda, Przemysław, et al.
Publicado: (2020)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
por: Duda, Przemysław, et al.
Publicado: (2020)

Cancer therapy and treatments during COVID-19 era
por: Akula, Shaw M., et al.
Publicado: (2020)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
por: Augello, Giuseppa, et al.
Publicado: (2020)

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2013)

The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
por: Martelli, Alberto M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_u9cgmkr817kcu7mi9m6kdnpns3